• Blog
  • Ulcerative Colitis Market Report

    Ulcerative Colitis Market Report

    Ulcerative Colitis Market Report
    Report code - SR2198 Delivery - 2 Weeks
    Get Free Sample |
    Ulcerative Colitis Market Size, Share, Trend, Forecast, Competitive Analysis, and Growth O See more...

    Market Insights

    The ulcerative colitis market was estimated at US$ 6.6 billion in 2021 and is expected to grow at a CAGR of 5.8% during 2022-2028 to reach US$ ~10.9 billion in 2028.

    Inflammation and ulcers on the inner lining of the large intestine are symptoms of the chronic inflammatory bowel disease (IBD) known as ulcerative colitis. Globally increasing rates of ulcerative colitis are promoting market expansion. The market is expanding as a result of rising investment in research & development capabilities to create novel treatments. Growing efforts by governmental and non-governmental organisations to conduct biologics research are also boosting the market for ulcerative colitis treatments.

    According to Arizton's prediction, the United States had the highest rate of inflammatory bowel disease incident cases in 2020, followed by China and the UK. The market for ulcerative colitis medications is expanding as the disease becomes more common. In the US, one million people were estimated to have inflammatory bowel illness in 2019.

    More than 155 trials in various stages of development are included in the clinical trial portfolio. The majority of industry-sponsored medications for inflammatory bowel disease in active clinical research are in Phase II, with three medications at the NDA/BLA stage. With 84% of studies in Phase I-II and only 16% in Phase III-IV, the distribution of clinical trials across Phase I-IV shows that the bulk of trials for ulcerative colitis have been in the primary and mid-stages of development. Worldwide, the US has a substantial advantage in the number of clinical studies for ulcerative colitis.

    With certain restrictions, the majority of drugs for UC are covered by both pharmacy and medical benefits. For all medications, more than half of the covered lives are enrolled in the pharmacy benefit's preferred tier, preferred with prior authorization, or step therapy, and covered tier, covered with PA/ST. The Entyvio Patient Assistance Programs provide product assistance to qualified patients who have been given a UC diagnosis. Through aid with co-pays, nurse support, and helpful advice, this initiative aims to benefit patients. EntyvioConnect may assist patients who have been prescribed the drug at every stage of the insurance approval procedure and works directly with eligible individuals to make sure they can afford the medication.

    The complex course of treatment for UC includes the administration of medications, dietary and nutritional changes, and occasionally, surgical operations to reconstruct or remove the patient's GI tract. Aminosalicylates, corticosteroids, immunomodulators, biologic treatments, and Janus kinase (JAK) inhibitors are some of the drugs being used for treatment. Combination therapies and dietary supplements are occasionally also advised.

    Surgery is recommended as the best alternative if the patient is no longer responding to medicine, if it is not working as well as it once did, or if the patient experiences frequent flare-ups.

    Anti-inflammatory pharmaceuticals with 5-aminosalicylic acid, including mesalazine sulfasalazine and olsalazine, are some of the regularly used medications for treating ulcerative colitis. Although corticosteroid drugs like budesonide and prednisone are also employed, they are often not given over an extended period of time due to their negative effects.

    If the illness is located in the colon, antibiotics may be recommended. Furthermore, a key aspect in the medications' successful positioning on the market is consumer awareness of ulcerative colitis treatment.

    Several investments/guidelines in the industry have been directed in recent years, which would boost the overall market. Some of them are:

    • In 2022, the USFDA approved the use of small molecules to treat moderate-to-severe ulcerative colitis, including Jyseleca (Filgotinib) and Rinvoq (Upadacitinib). The market for ulcerative colitis treatments will experience significant expansion as a result of the introduction of authorised small molecules and continued adoption of biological therapies.
    • The market under study has shown significant expansion, which is attributable to the rising incidence of inflammatory bowel disease across the globe. In 2018, there were 910,000 cases of inflammatory bowel disease in the United States, according to estimates.

    Segment Analysis

    The market is divided based on disease type, molecule type, and route of administration. On the basis of disease type, the market is further segmented into mild, moderate, and severe. The moderate segment is expected to grow highest over the anticipated period.

    Based on molecule type, the ulcerative colitis market has been divided into biologics and small molecules. The biologcs segment is expected to hold the major share owing to the high awareness.

    The ulcerative colitis market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2021, North America is anticipated to be the ulcerative colitis market's largest region. Due to improved healthcare costs, more public understanding and awareness, and technological innovation in the US, this country dominates the ulcerative colitis market. However, the UK is anticipated to grow more quickly and with a high CAGR in the ulcerative colitis drug market due to improvements in healthcare access and quality, a rise in disease management knowledge, and rising healthcare spending in this area. The popularity of biosimilars in developing nations like China and Japan may change the therapeutic environment here.

    Key Players

    The market for ulcerative colitis is highly competitive. The state of the economy and government assistance have a direct impact on the expansion of the businesses. Based on their product's quality and market penetration in both the target and growing markets, these companies distinguish their ulcerative colitis driver in the industry. Furthermore, recent important mergers and acquisitions in the sector have had a big impact on the dynamics of competition. For instance:
    • In 2022, the US FDA approved small molecules, namely, Jyseleca (Filgotinib) and Rinvoq (Upadacitinib) to treat moderate to severe cases of ulcerative colitis.
    • In October 2022, The National Institute for Health and Care Excellence (NICE) has recommended Bristol Myers Squibb's (BMS) Zeposia (ozanimod) for the treatment of adults with moderate-to-severe active ulcerative colitis (UC). This is the first time that NICE has recommended an oral sphingosine 1-phosphate (S1P) receptor modulator for the treatment of UC. The advice is specifically for individuals whose conditions have not responded well to earlier biologic therapy or conventional therapy, or who are intolerant of it.
    • In July 2021, Bristol Myers Squibb reported that neither the primary efficacy endpoint of clinical remission at Week 12 nor the secondary efficacy endpoints were met in the Phase 2 LATTICE-UC study comparing deucravacitinib, a first-in-class oral selective tyrosine kinase 2 (TYK2) inhibitor, to placebo in patients with moderate to severe ulcerative colitis (UC). Deucravacitinib's safety profile was similar with trials on psoriasis and psoriatic arthritis that have already been published, and no new safety signals were noticed.
    The overall competitive landscape has been affected due to these mergers and acquisitions. The following are the major players in the ulcerative colitis market:
    • AbbVie Inc
    • Bristol-Myers Squibb
    • CellTrion
    • EA Pharma
    • Eli Lilly and Company
    • InDex
    • Johnson & Johnson
    • Pfizer Inc 
    • Reistone Biopharma Co. Ltd.
    • Takeda Pharmaceutical Co Ltd.

    Research Methodology

    This report offers high-quality insights and is the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact book, press release, journals, investor presentation, white papers, patents, and articles have been leveraged to gather the data. We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both the qualitative and quantitative insights.

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:

    • Market structure: Overview, industry life cycle analysis, supply chain analysis
    • Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis
    • Market trend and forecast analysis
    • Market segment trend and forecast
    • Competitive landscape and dynamics: Market share, product portfolio, product launches, etc.
    • Attractive market segments and associated growth opportunities
    • Emerging trends
    • Strategic growth opportunities for the existing and new players
    • Key success factors

    Frequently Asked Questions (FAQ)

    The ulcerative colitis market was valued at US$ 6.6 billion in 2021.

    The ulcerative colitis market reach at US$ ~10.9 billion in 2028.

    The market is growing at a CAGR of 5.8% over the forecast period.

    Globally increasing rates of ulcerative colitis are promoting market expansion. The market is expanding as a result of rising investment in research & development capabilities to create novel treatments. Growing efforts by governmental and non-governmental organisations to conduct biologics research are also boosting the market for ulcerative colitis treatments.

    The major players in the ulcerative colitis market are AbbVie Inc, Bristol-Myers Squibb, CellTrion, EA Pharma, Eli Lilly and Company, InDex, Johnson & Johnson, Pfizer Inc, Reistone Biopharma Co. Ltd., Takeda Pharmaceutical Co Ltd.

    Inflammation and ulcers on the inner lining of the large intestine are symptoms of the chronic inflammatory bowel disease (IBD) known as ulcerative colitis.

    In 2021, North America is anticipated to be the ulcerative colitis market's largest region. Due to improved healthcare costs, more public understanding and awareness, and technological innovation in the US, this country dominates the ulcerative colitis market.

    The ulcerative colitis market is studied from 2016 - 2028.